Since the anti-VEGF antibody bevacizumab is approved for clinical use in GBM, whereas no VEGFR TKIs are approved, we switched to using an analog of bevacizumab, B20S, that binds to and sequesters mouse VEGF. This evidence concerns the gene KDR and glioblastoma.